Amgen's Imdelltra for Advanced Lung Cancer Wins Accelerated US Approval

May 16, 2024, 07:09 PM

Amgen has received US FDA accelerated approval for its new drug, Imdelltra, designed to treat adult patients with advanced small cell lung cancer. The approval, granted on May 16, 2024, marks a significant step in the fight against this particularly aggressive form of cancer. The drug, also known as tarlatamab, is a targeted immunotherapy aimed at patients whose condition has worsened despite chemotherapy.